Allogene Therapeutics Inc. (ALLO) carries a Roarable Rating of E (Strong Sell) with 33/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
As of 2026-11-03, Allogene Therapeutics Inc. (NASDAQ: ALLO) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 33/100 at a spot price of $1.09 (-7.63% 1D, market cap $407.7M). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 8/20, and Executive Insider Alignment 5/20. Across 1015 tracked Health Care issuers, ALLO ranks #675 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), ALLO carries a Roarable E (33/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, EDIT (Editas Medicine Inc.) holds a E grade (29/100 RQD, P/E N/A, ROIC -35.0%, cap $410.1M) and AUTL (Autolus Therapeutics plc) posts a E grade (21/100 RQD, P/E N/A, ROIC -35.0%, cap $404.6M). Among the 5-stock peer group, ALLO leads on earnings multiple (N/A) while ALLO leads on capital efficiency (-35.0% ROIC).
Per ALLO's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001737287), Allogene Therapeutics Inc. generated $586.1M in revenue (+2663909.1% YoY), -$190.9M in net income, and -$149.6M in free cash flow against $415.9M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 3/9
FRED Regime × Technicals: 2% of 52W Range • RSI-14 at 33.4 (NEUTRAL RANGE)
Put hedging (50% put share) caps near-term gamma upside (-16 pts vs max)
While ALLO currently carries a cautious 33/100 (E) rating due to Whale & Options Positioning (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
Established market leader in Health Care with deep daily trading liquidity.
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($1.58) and Max Pain ($1.14) forces dealer call-delta covering toward $4.68.
Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
Allogene Therapeutics Inc. (ALLO) dropped -7.63% to $1.09, trading at 2% of its 52-week range ($1.04 – $4.46). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
Yahoo! Finance Canada report covering Allogene Therapeutics Inc. (ALLO) market action, institutional positioning, and fundamental catalysts.
Investing.com report covering Allogene Therapeutics Inc. (ALLO) market action, institutional positioning, and fundamental catalysts.
www.debelegger.nl report covering Allogene Therapeutics Inc. (ALLO) market action, institutional positioning, and fundamental catalysts.
TradingView report covering Allogene Therapeutics Inc. (ALLO) market action, institutional positioning, and fundamental catalysts.
MarketBeat report covering Allogene Therapeutics Inc. (ALLO) market action, institutional positioning, and fundamental catalysts.
Value Research report covering Allogene Therapeutics Inc. (ALLO) market action, institutional positioning, and fundamental catalysts.
Stock Titan report covering Allogene Therapeutics Inc. (ALLO) market action, institutional positioning, and fundamental catalysts.
Yahoo Finance UK report covering Allogene Therapeutics Inc. (ALLO) market action, institutional positioning, and fundamental catalysts.
Q3 2026 Financial Results and Business Update Conference Call and Webcast Scheduled for November 5, 2026 at 2:00 p.m. PT/5:00 p.m. ETALLO-329 Autoimmune Disease Program Webinar Featuring Preliminary Safety and Efficacy D
SOUTH SAN FRANCISCO, Calif., Oct. 26, 2026 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T) products for ca
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +2663909.1% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on ALLO today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for ALLO. Explore sector supply chains on /butterfly.
Across 1015 tracked Health Care securities in the Roarable RQD universe, Allogene Therapeutics Inc. (ALLO) ranks #675 by composite RQD confidence (33/100, grade E) and #471 by equity capitalization ($407.7M). Within this direct 5-issuer industry benchmark cohort, ALLO leads on earnings valuation at N/A trailing P/E, while ALLO leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. PROK currently holds the highest overall quantitative score in the immediate peer group at 35/100 (D-) compared with ALLO at 33/100 (E).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| ALLO
ACTIVE
Allogene Therapeutics Inc. | E | 33/100 | — | — | -35.0% | -7.63% | $407.7M | Benchmark Subject |
| EDIT Editas Medicine Inc. | E | 29/100 | — | — | -35.0% | -3.74% | $410.1M | /edit-vs-allo → |
| AUTL Autolus Therapeutics plc | E | 21/100 | — | -27.8% | -35.0% | -6.58% | $404.6M | /autl-vs-allo → |
| CCCC C4 Therapeutics Inc. | E | 29/100 | — | — | -35.0% | -4.75% | $414.6M | /cccc-vs-allo → |
| PROK ProKidney Corp. (Class A) | D- | 35/100 | — | — | -35.0% | -13.51% | $391.6M | /prok-vs-allo → |
In its most recent audited fiscal period (FY2025, filed 2025-12-31), Allogene Therapeutics Inc. (ALLO) reported GAAP revenue of $586.1M (+2663909.1% vs. FY2024 revenue of $22.0K , and +616828.4% cumulative change since FY2023) , GAAP net income of -$190.9M, operating cash flow of -$149.2M, and free cash flow of -$149.6M (+25.6% YoY). On the balance sheet, ALLO closed FY2025 with $415.9M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 3/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $586.1M | -$190.9M | -$149.2M | -$149.6M | $415.9M | — |
| FY2024 (FY) | 2024-12-31 | $22.0K | -$257.6M | -$200.3M | -$201.0M | $548.7M | — |
| FY2023 (FY) | 2023-12-31 | $95.0K | -$327.3M | -$237.7M | -$237.7M | — | — |
As of 2026-11-03, Allogene Therapeutics Inc. (NASDAQ: ALLO) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 33/100 at a spot price of $1.09 (-7.63% 1D, market cap $407.7M). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 8/20, and Executive Insider Alignment 5/20. Across 1015 tracked Health Care issuers, ALLO ranks #675 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), ALLO carries a Roarable E (33/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, EDIT (Editas Medicine Inc.) holds a E grade (29/100 RQD, P/E N/A, ROIC -35.0%, cap $410.1M) and AUTL (Autolus Therapeutics plc) posts a E grade (21/100 RQD, P/E N/A, ROIC -35.0%, cap $404.6M). Among the 5-stock peer group, ALLO leads on earnings multiple (N/A) while ALLO leads on capital efficiency (-35.0% ROIC).
Per ALLO's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001737287), Allogene Therapeutics Inc. generated $586.1M in revenue (+2663909.1% YoY), -$190.9M in net income, and -$149.6M in free cash flow against $415.9M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.
ALLO last traded at $1.09 (-7.63% on volume of 10,058,438 shares), positioning the stock -31.01% below its 50-day simple moving average ($1.58) and -44.95% below its 200-day simple moving average ($1.98). Across its 52-week range of $1.04 to $4.46, ALLO sits at the 1.5% percentile with a 14-day RSI of 33.4 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.00 to $1.23).
Allogene Therapeutics Inc. (ALLO) earns a live Roarable RQD composite score of 33/100, corresponding to a E letter grade (Roarable Strong Sell) at a spot price of $1.09 (-7.63% 1D, market capitalization $407.7M).
Allogene Therapeutics Inc. Is a NASDAQ-listed issuer in the Health Care sector, classified under Biotechnology: Biological Products (No Diagnostic Substances). The market capitalization is $0.4B. Reported revenue is — in FY 2025, — in FY 2024, and $0.1M in FY 2023, indicating no meaningful commercial revenue in the reported periods.
In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Allogene Therapeutics Inc. (ALLO) reported $586.1M in annual revenue (up from $22.0K in FY2024, +2663909.1% YoY) and -$190.9M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($95.0K revenue, -$327.3M net income) through FY2025, ALLO scaled operating cash flow to -$149.2M and free cash flow to -$149.6M, backed by $415.9M in total assets against $0 in total debt.
The source data therefore provides no upstream supplier, downstream customer, or cross-sector dependency mapping. The only sector context available is the classification of Health Care / Biotechnology: Biological Products. For a prospective investor, the absence of mapped dependencies means second-order ripple effects cannot be identified from the provided sources; any concentration or partner-dependency risk for a clinical-stage profile of this type would need to be verified from primary filings outside this dataset.
Real-time company headlines, analyst actions, and sector developments for Allogene Therapeutics Inc. (ALLO) • Click "Debate This Headline" to argue it in the Roar Pit below
Yahoo! Finance Canada report covering Allogene Therapeutics Inc. (ALLO) market action, institutional positioning, and fundamental catalysts.
Investing.com report covering Allogene Therapeutics Inc. (ALLO) market action, institutional positioning, and fundamental catalysts.
www.debelegger.nl report covering Allogene Therapeutics Inc. (ALLO) market action, institutional positioning, and fundamental catalysts.
TradingView report covering Allogene Therapeutics Inc. (ALLO) market action, institutional positioning, and fundamental catalysts.
MarketBeat report covering Allogene Therapeutics Inc. (ALLO) market action, institutional positioning, and fundamental catalysts.
Value Research report covering Allogene Therapeutics Inc. (ALLO) market action, institutional positioning, and fundamental catalysts.
Stock Titan report covering Allogene Therapeutics Inc. (ALLO) market action, institutional positioning, and fundamental catalysts.
Yahoo Finance UK report covering Allogene Therapeutics Inc. (ALLO) market action, institutional positioning, and fundamental catalysts.
The street is overcomplicating Allogene Therapeutics Inc. (ALLO). The balance sheet pillar (10/20, Altman Z 2.5, Debt/Equity 0.5) is the strongest of the five RQD pillars, and the stock trades near the bottom of its $1.04–$4.46 52-week range.. With an RQD score of 33/100 (E) and Forensic Balance Sheet at 10/20, any positive earnings surprise or guidance raise forces underweight funds to chase above $1.27.
@AlphaFlow_Cap Agree on the RQD 33/100 quality, though with 1.0 beta I'm scaling in with half-size at $1.18 and keeping dry powder in case we test $1.10.
I respect the product at Allogene Therapeutics Inc., but the stock at $1.18 is a different story. ROIC of -35%, FCF of -$149.6M in FY 2025, and cash falling from $75.2M to $51.7M, with insider and institutional pillars scoring 5/20 and 3/20.. FCF yield is 0.0% and RQD sits at 33/100 (E) — why pay up here when you can wait for next quarter's numbers?
To protect compute speed and zero-delay Cboe BZX data quality for active members, our current $9.95/month Roarable Pro cohort is 100% full. Join the priority waiting list below and we will notify you the moment the next batch of Pro accounts opens (and lock in your $9.95/mo rate).
Link your personal ChatGPT, Claude Desktop, or Cursor via Roarable's Model Context Protocol (`mcp.roarable.com`) to query all 5,289 stocks, inspect Butterfly supply chains, and trade your `$100K Arena` account.
Interrogate SEC 10-K/10-Q filings on demand and ask custom ticker, valuation, or short-thesis questions directly to any of our 8 specialized AI Quant Analysts.
Command our AI agents to sort and sift 5,289 stocks by custom formulas, follow multi-indicator technical & cash-flow setups, and send you instant Email/SMS breakout & downgrade alerts.
Unlock sub-second Cboe BZX streaming quotes, pre-market/after-hours delta scanners, instant SEC Form 4 insider cluster alerts, and unlimited portfolio stress-testing.
All 8 Roarable Analysts (Mara Quenwick, Gideon Ashmere, Ellis Vennor, Tessa Rookmere, Soren Halewick, Iona Brackenford, Nadia Vellacrest, and Felix Orven) are proprietary AI Quant Analysts and automated algorithmic specialists — not human financial advisors, fiduciaries, or registered broker-dealers. While one-to-many daily stock ratings and briefings are free, custom 1-on-1 Q&A, custom AI sifting/indicator alert agents, and personal ChatGPT/Claude MCP connections consume dedicated per-user compute and require a $9.95/month Roarable Pro membership. All AI outputs are for educational and research purposes only and never constitute individualized investment advice.
Enter your email address below for instant 1-step account activation, daily A–E stock rating alerts, and immediate access to your $100,000.00 Virtual Cash Arena account (100% free — no credit card required).